{"product_id":"anti-human-ms4a1-and-cd3e-bispecific-reference-antibody-mosunetuzumab-bha21415840","title":"Anti-Human MS4A1 \u0026 CD3E Bispecific Reference Antibody (Mosunetuzumab)","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eReference Antibody\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cstrong\u003eResearch Grade Mosunetuzumab\u003c\/strong\u003e (HY257166) is a \u003cstrong\u003ehumanized monoclonal\u003c\/strong\u003e antibody detecting B-lymphocyte surface antigen B1 in \u003cstrong\u003eELISA, Bioactivity: FACS, Functional assay, Research in vivo\u003c\/strong\u003e. Suitable for \u003cstrong\u003eHuman\u003c\/strong\u003e.\n\n\nHighlights\n\u003cul\u003e\n\u003cli\u003e●\u003cstrong\u003eMulti-Application\u003c\/strong\u003e — Validated across multiple applications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eHost Species\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies Reactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1, kappa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eB-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20, T3E, T-cell surface antigen T3\/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eProtein A\/G purified from cell culture supernatant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% purity as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage Buffer\u003c\/th\u003e\n\u003ctd\u003e0.01M PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression System\u003c\/th\u003e\n\u003ctd\u003eMammalian Cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eUniProt\u003c\/th\u003e\n\u003ctd\u003eP11836, P07766\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\u003cth\u003eApplication\u003c\/th\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eELISA\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFlow Cytometry\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFunctional Assay\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIn Vivo Studies\u003c\/td\u003e\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eEpcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed\/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed\/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.\u003c\/p\u003e\n\u003ch2\u003eReactivity\u003c\/h2\u003e\n\u003cp\u003eThis antibody shows reactivity with Human.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003eFor Research Use Only (RUO). Not for use in diagnostic or therapeutic procedures.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Biohippo Inc","offers":[{"title":"1 mg","offer_id":53513344745837,"sku":"HY257166-1MG","price":352.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53513522741613,"sku":"HY257166-5MG","price":700.0,"currency_code":"USD","in_stock":true},{"title":"10 mg","offer_id":53513522774381,"sku":"HY257166-10MG","price":1000.0,"currency_code":"USD","in_stock":true},{"title":"25 mg","offer_id":53513522807149,"sku":"HY257166-25MG","price":1800.0,"currency_code":"USD","in_stock":true},{"title":"50 mg","offer_id":53513522839917,"sku":"HY257166-50MG","price":2800.0,"currency_code":"USD","in_stock":true},{"title":"100 mg","offer_id":53513522872685,"sku":"HY257166-100MG","price":4600.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/HY257166-SDS-PAGE-1.jpg?v=1783375462","url":"https:\/\/www.ebiohippo.com\/products\/anti-human-ms4a1-and-cd3e-bispecific-reference-antibody-mosunetuzumab-bha21415840","provider":"BioHippo","version":"1.0","type":"link"}